Atlas Four · Vaccine Atlas · Platform 05 — Live-Attenuated

MMR Vaccine (M-M-R II / Priorix)

Live-attenuated measles-mumps-rubella vaccine. Two-dose schedule achieves >97% seroconversion; 95% coverage required for measles herd immunity. Wakefield 1998 paper (retracted 2010) falsely linked MMR to autism — refuted by >15 large cohort studies.

05 — Live-AttenuatedPlatform
subcutaneousRoute
2–8°C (in dark); reconstituted vaccine must be used within 8 hours; discard unused reconstituted vaccineCold Chain
activeStatus
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
mmr-vaccine

MMR Vaccine (M-M-R II / Priorix)

Live-attenuated measles-mumps-rubella vaccine. Two-dose schedule achieves >97% seroconversion; 95% coverage required for measles herd immunity. Wakefield 1998 paper (retracted 2010) falsely linked MMR to autism — refuted by >15 large cohort studies.

Entry Metadata

FieldValue
IDmmr-vaccine
NameMMR Vaccine (M-M-R II / Priorix)
Statusactive
Last reviewed2026-06-06
Platform05 — Live-Attenuated
Delivery systemlyophilized live attenuated viruses
AdjuvantsNone
Routesubcutaneous
Dose scheduleDose 1: 12–15 months; Dose 2: 4–6 years. Minimum interval: 4 weeks between doses.
ManufacturerMerck (M-M-R II); GSK (Priorix); Serum Institute of India (Tresivac); sanofi (discontinued)
Cold chain2–8°C (in dark); reconstituted vaccine must be used within 8 hours; discard unused reconstituted vaccine

Cross-Atlas Connections

immunizes-againstMeasles Virus platform-peerVaricella Zoster Virus connects-toImmune System connects-toImmunoglobulin G

Sources